APPENDIX
2C

Pfizer's Response to ALLHAT, 20 April 2001

Appendix 2C: Treatment emergent, All Causality Incidence of Selected Cardiovascular Events, By Protocol ID

Protocol ID	····Median Duration····· Doxazosin (Days)	Pooled Compar (Days)	Total # of Subjects on Doxazosin	Total # of Subjects on Pooled Comparators**	····· Doxazosin/Doxazosin GITS ····· Number(%) of Subjects with CHF	Number(%) of Subjects with MI	Number(%) of Subjects with Stroke	····· Pooled Comarators ····· Number(%) of Subjects with CHF	Number(%) of Subjects with MI	Number(%) of Subjects with Stroke
D421	97	98	199	49	0	0	0	0	0	0
D421L	820		178		2(1.12%)	2(1.12%)	4(2.25%)	-	-	-
D488	84	84	211	50	0	0	1(0.47%)	0	0	0
D488L	1093		200		1(0.50%)	6(3.00%)	3(1.50%)	-	-	-
D490	98	98	50	50	0	0	0	0	0	0
D490L	805		72		0	0	1(1.39%)	-	-	-
D606	168	169	119	113	1(0.84%)	0	0	0	0	0
D606L	168		131		0	2(1.53%)	0	-	-	-
DAZ-A-88-001	117	113	33	30	0	0	0	0	0	0
DAZ-A-89-001	90		927		0	0	1(0.11%)	-	-	-
DAZ-AR-96-001	70		230		0	0	0	-	-	-
DAZ-AR-96-002	70		266		0	0	0	-	-	-
DAZ-AUS-88-001	135	64	24	21	0	0	0	-	-	-
DAZ-AUS-88-002	82	49	19	20	0	0	0	0	0	0
DAZ-AUS-89-005	70	71	27	24	0	0	0	0	0	0
DAZ-AUS-90-002	42	21	4	5	0	0	0	0	0	0
DAZ-BAN-88-001	16		27		0	1(3.70%)	0	-	-	-
DAZ-BRA-95-002	98		35		0	0	0	-	-	-
DAZ-BRA-96-001	27		689		0	0	0	-	-	-
DAZ-CDN-86-001	339		20		0	0	0	-	-	-
DAZ-CDN-87-002	210	218	96	95	0	0	0	0	0	0
DAZ-CDN-87-002E	360		44		0	0	0	..	-	-
DAZ-COL-96-001	103		127		0	0	0	-	-	-
DAZ-CR-96-001	126		34		0	1(2.94%)	0	-	-	-
DAZ-CZ-97-001	85		328		0	0	0	-	-	-
DAZ-D-85-001	84	84	27	27	0	0	0	0	0	0
DAZ-D-85-003	350	350	32	29	0	0	0	0	0	0
DAZ-D-86-001	88		34		0	0	0	-	-	-
DAZ-D-86-006	56		20		0	0	0	-	-	-
DAZ-D-87-007B	112	112	46	48	0	0	0	0	0	0
DAZ-D-88-110	84		1584		0	3(0.19%)	3(0.19%)	-	-	-
DAZ-D-89-202	183	183	322	155	0	0	0	0	0	0
DAZ-D-89-204	84		14		0	0	0	-	-	-
DAZ-D-89-205	35		23		0	0	0	-	-	-
DAZ-D-89-PMS1(AB)	90		19035		10(0.05%)	9(0.05%)	5(0.03%)	-	-	-
DAZ-D-90-302	167		20		0	0	0	-	-	-
DAZ-D-91-403	172	179	15	13	0	0	0	0	0	0
DAZ-D-AB-90	89		1807		0	0	2(0.11%)	-	-	-

**Pooled Comparators includes Placebo and Active Comparators

Date of Table Generation: 17APR2001 13:25:33

Source Data: Appendix 18 - Master, PPG NYHQ Released Project Databases, and BPH NDA

Program Name: L:\SAFETY\CSD\REPORTS\DAZ_ALLHAT_28FEB2001\PGM\APPENDIX 2C.SAS

Pfizer's Response to ALLHAT, 20 April 2001
Appendix 2C: Treatment emergent, All Causality Incidence of Selected Cardiovascular Events, By Protocol ID

	••••Median Duration•••••				••••• Doxazosin/Doxazosin GITS ••••••			••••••••• Pooled Comarators •••••••••		
Protocol ID	Doxazosin (Days)	Pooled Compar (Days)	Total # of Subjects on Doxazosin	Total # of Subjects on Pooled Comparators**	Number(%) of Subjects with CHF	Number(%) of Subjects with MI	Number(%) of Subjects with Stroke	Number(%) of Subjects with CHF	Number(%) of Subjects with MI	Number(%) of Subjects with Stroke
DAZ-D-AB-91	92		772		0	0	0	-	-	-
DAZ-DK-86-002	24	24	44	50	0	0	0	0	0	0
DAZ-DK-87-004	7	2	93	187	0	0	0	0	0	0
DAZ-DK-87-005	374	366	40	43	1(2.50%)	1(2.50%)	0	0	0	0
DAZ-DK-94-001	70	70	13	15	0	0	0	0	0	0
DAZ-E-85-001	180	181	32	33	0	0	1(3.13%)	0	0	0
DAZ-E-85-002	12	14	33	36	0	0	0	0	0	0
DAZ-E-87-002	11		236		0	0	0	-	-	-
DAZ-E-89-002	8	6	31	30	0	0	0	0	0	0
DAZ-E-90-001	154		35		0	0	0	-	-	-
DAZ-E-91-006	98		53		0	0	0	-	-	-
DAZ-E-91-007	335		81		0	0	0	-	-	-
DAZ-E-92-001	98		40		0	0	0	-	-	-
DAZ-E-94-001	168	168	19	16	0	0	0	0	0	0
DAZ-E-95-001	70	70	35	34	0	0	0	0	0	0
DAZ-E-95-002	84		15		0	0	0	-	-	-
DAZ-E-95-004	98	98	41	39	0	0	0	0	0	0
DAZ-ECU-94-001	196		30		0	0	0	-	-	-
DAZ-EG-87-001	31		50		0	0	0	-	-	-
DAZ-EG-88-001	70		50		0	0	0	-	-	-
DAZ-EG-88-002	90		30		0	0	0	-	-	-
DAZ-EG-89-001	106		25		0	0	0	-	-	-
DAZ-EG-94-001	84		30		0	0	0	-	-	-
DAZ-EG-95-001	84		38		0	0	0	-	-	-
DAZ-EG-95-002	84		30		0	0	0	-	-	-
DAZ-EG-98-001	90		43		0	0	0	-	-	-
DAZ-I-86-001	8	8	40	40	0	0	0	0	0	0
DAZ-I-87-001	14		10		0	0	0	-	-	-
DAZ-I-87-002	28	28	24	24	0	0	0	0	0	0
DAZ-I-88-001	28		11		0	0	0	-	-	-
DAZ-I-88-002	14	14	10	10	0	0	0	0	0	0
DAZ-I-88-003	49	42	10	10	0	0	0	0	0	0
DAZ-I-89-001	154	154	36	34	0	0	0	0	0	0
DAZ-I-89-002	154	154	40	40	0	0	0	0	0	0
DAZ-I-89-003A	183		541		0	0	0	-	-	-
DAZ-I-89-003B	178		1325		0	0	0	-	-	-
DAZ-I-91-001	169		50		0	0	0	-	-	-
DAZ-I-91-002	168		85		0	0	0	-	-	-

**Pooled Comparators includes Placebo and Active Comparators
Date of Table Generation: 17APR2001 13:25:33
Source Data: Appendix 18 - Master, PPG NYHQ Released Project Databases, and BPH NDA
Program Name: L:\SAFETY\CSD\REPORTS\DAZ_ALLHAT_28FEB2001\PGM\APPENDIX 2C.SAS

Appendix 2C: Treatment emergent, All Causality Incidence of Selected Cardiovascular Events, By Protocol ID

	••••Median Duration•••••				••••• Doxazosin/Doxazosin GITS •••••			••••••••• Pooled Comarators •••••••••		
Protocol ID	Doxazosin (Days)	Pooled Compar (Days)	Total # of Subjects on Doxazosin	Total # of Subjects on Pooled Comparators**	Number(%) of Subjects with CHF	Number(%) of Subjects with MI	Number(%) of Subjects with Stroke	Number(%) of Subjects with CHF	Number(%) of Subjects with MI	Number(%) of Subjects with Stroke
DAZ-I-92-001	85		164		0	0	0	-	-	-
DAZ-I-92-002	86		48		0	0	0	-	-	-
DAZ-I-92-003	56		90		0	1(1.11%)	0	-	-	-
DAZ-I-92-005	10	10	15	15	0	0	0	0	0	0
DAZ-I-94-001	170	169	31	12	0	0	0	0	0	0
DAZ-I-95-002	373		25		0	0	0	-	-	-
DAZ-II-94-001	56		113		0	0	0	-	-	-
DAZ-IND-90-002	6		26		0	0	0	-	-	-
DAZ-JP-90-001	15		9		0	0	0	-	-	-
DAZ-JP-90-002	24		15		0	0	0	-	-	-
DAZ-JP-90-003	12		23		0	0	0	-	-	-
DAZ-JP-90-004	12		17		0	0	0	-	-	-
DAZ-JP-90-005	8		21		0	0	0	-	-	-
DAZ-JP-90-006	85		16		0	0	0	-	-	-
DAZ-JP-91-004	53		8		0	0	0	-	-	-
DAZ-JP-91-005	14		50		0	0	0	-	-	-
DAZ-JP-91-006	12		20		0	0	0	-	-	-
DAZ-JP-91-007	12		12		0	0	0	-	-	-
DAZ-JP-91-008	12		11		0	0	0	-	-	-
DAZ-JP-91-010	12		14		0	0	0	-	-	-
DAZ-JP-91-011	13		15		0	0	0	-	-	-
DAZ-JP-91-012	12		39		0	0	0	-	-	-
DAZ-JP-91-013	16		19		0	0	0	-	-	-
DAZ-JP-91-014	20		26		0	0	0	-	-	-
DAZ-JP-91-015	115		11		0	0	0	-	-	-
DAZ-JP-91-016	240		10		0	0	0	-	-	-
DAZ-JP-92-001	89		29		0	0	0	-	-	-
DAZ-JP-92-003	30		8		0	0	0	-	-	-
DAZ-JP-92-004	533		16		0	0	0	-	-	-
DAZ-JP-92-005	29		8		0	0	0	-	-	-
DAZ-JP-92-006	13		22		0	0	0	-	-	-
DAZ-JP-92-007	12		24		0	0	0	-	-	-
DAZ-JP-92-008	84		22		0	0	0	-	-	-
DAZ-JP-92-009	85		14		0	0	0	-	-	-
DAZ-JP-92-012	96		23		0	0	0	-	-	-
DAZ-JP-92-015	13		5		0	1(20.00%)	0	-	-	-
DAZ-JP-92-016	12		25		0	0	0	-	-	-
DAZ-JP-92-017	15		23		0	0	0	-	-	-

**Pooled Comparators includes Placebo and Active Comparators
Date of Table Generation: 17APR2001 13:25:33
Source Data: Appendix 18 - Master, PPG NYHQ Released Project Databases, and BPH NDA
Program Name: L:\SAFETY\CSD\REPORTS\DAZ_ALLHAT_28FEB2001\PGM\APPENDIX 2C.SAS

Pfizer's Response to ALLHAT, 20 April 2001

Appendix 2C: Treatment emergent, All Causality Incidence of Selected Cardiovascular Events, By Protocol ID

Protocol ID	••••Median Duration••••• Doxazosin (Days)	Pooled Compar (Days)	Total # of Subjects on Doxazosin	Total # of Subjects on Pooled Comparators**	••••• Doxazosin/Doxazosin GITS ••••• Number(%) of Subjects with CHF	Number(%) of Subjects with MI	Number(%) of Subjects with Stroke	••••••••• Pooled Comarators ••••••••• Number(%) of Subjects with CHF	Number(%) of Subjects with MI	Number(%) of Subjects with Stroke
DAZ-JP-92-020	12		18		0	0	0	-	-	-
DAZ-JP-93-003	12		19		0	0	0	-	-	-
DAZ-JP-93-007	15		14		0	0	0	-	-	-
DAZ-JP-93-008	90		21		0	0	0	-	-	-
DAZ-JP-93-010	24		7		0	0	0	-	-	-
DAZ-JP-93-202	12		86		0	0	0	-	-	-
DAZ-JP-93-205	12		61		0	0	0	-	-	-
DAZ-JP-93-207	368		253		0	0	0	-	-	-
DAZ-JP-93-208	13		94		0	0	0	-	-	-
DAZ-JP-93-209	12		39		0	0	0	-	-	-
DAZ-JP-93-210	13		82		0	0	0	-	-	-
DAZ-JP-93-211	16		41		0	0	0	-	-	-
DAZ-JP-93-212	18		39		0	0	0	-	-	-
DAZ-JP-93-213	173		38		0	0	0	-	-	-
DAZ-JP-93-215	168		376		0	2(0.53%)	0	-	-	-
DAZ-JP-93-216	12		23		0	0	0	-	-	-
DAZ-JP-93-217	26		122		0	0	0	-	-	-
DAZ-JP-93-218	166		110		0	0	2(1.82%)	-	-	-
DAZ-JP-93-219	24		117		0	0	0	-	-	-
DAZ-JP-93-220	24		57		0	0	0	-	-	-
DAZ-JP-93-221	12		24		0	0	0	-	-	-
DAZ-JP-93-222	24		89		0	0	0	-	-	-
DAZ-JP-93-223	16		70		0	0	0	-	-	-
DAZ-JP-93-224	12		24		0	0	0	-	-	-
DAZ-JP-93-225	26		93		0	0	0	-	-	-
DAZ-JP-93-226	12		69		0	0	0	-	-	-
DAZ-JP-93-227	12	12	23	17	0	0	0	0	0	0
DAZ-JP-93-228	84	84	68	13	0	0	0	-	-	-
DAZ-JP-93-230	24		53		0	0	0	-	-	-
DAZ-JP-93-231	12		120		0	0	0	-	-	-
DAZ-JP-93-232	17		35		0	0	0	-	-	-
DAZ-JP-93-233	24		30		0	0	0	-	-	-
DAZ-JP-93-234	24		80		0	0	0	-	-	-
DAZ-JP-93-235	24		135		0	0	0	-	-	-
DAZ-JP-94-201	121		1		0	0	0	-	-	-
DAZ-JP-94-203	12		20		0	0	0	-	-	-
DAZ-JP-94-204	26		15		0	0	0	-	-	-
DAZ-JP-94-206	16		6		0	0	0	-	-	-

**Pooled Comparators includes Placebo and Active Comparators

Date of Table Generation: 17APR2001 13:25:33

Source Data: Appendix 18 - Master, PPG NYHQ Released Project Databases, and BPH NDA

Program Name: L:\SAFETY\CSD\REPORTS\DAZ_ALLHAT_28FEB2001\PGM\APPENDIX 2C.SAS

Appendix 2C: Treatment emergent, All Causality Incidence of Selected Cardiovascular Events, By Protocol ID

	••••Median Duration•••••				••••• Doxazosin/Doxazosin GITS ••••••			••••••••• Pooled Comarators •••••••••		
Protocol ID	Doxazosin (Days)	Pooled Compar (Days)	Total # of Subjects on Doxazosin	Total # of Subjects on Pooled Comparators**	Number(%) of Subjects with CHF	Number(%) of Subjects with MI	Number(%) of Subjects with Stroke	Number(%) of Subjects with CHF	Number(%) of Subjects with MI	Number(%) of Subjects with Stroke
DAZ-JP-94-207	12		10		0	0	0	-	-	-
DAZ-JP-94-208	13		3		0	0	0	-	-	-
DAZ-JP-94-209	8		7		0	0	0	-	-	-
DAZ-JP-94-210	12		11		0	0	0	-	-	-
DAZ-JP-95-001	85		18		0	0	0	-	-	-
DAZ-JP-96-001	99	92	20	20	0	0	0	0	0	0
DAZ-JP-96-002	164	185	6	6	0	0	0	0	1(16.67%)	0
DAZ-K-84-001	10		97		0	0	0	-	-	-
DAZ-K-87-001	15		67		0	0	0	-	-	-
DAZ-K-87-003	12		14		0	0	0	-	-	-
DAZ-K-88-001	8		21		0	0	0	-	-	-
DAZ-K-90-001	13	13	30	30	0	0	0	0	0	0
DAZ-K-90-002	8		20		0	0	0	-	-	-
DAZ-K-90-003	12		20		0	0	0	-	-	-
DAZ-K-95-003	30		116		0	0	0	-	-	-
DAZ-MAL-87-002	26		27		0	0	0	-	-	-
DAZ-MAL-90-001	12		6		0	0	0	-	-	-
DAZ-MEX-86-001	16		29		0	0	0	-	-	-
DAZ-MEX-86-002	12		21		0	0	0	-	-	-
DAZ-MEX-96-001	108		111		0	0	0	-	-	-
DAZ-MOR-96-001	58		138		0	0	0	-	-	-
DAZ-MOR-96-002	91		45		0	0	0	-	-	-
DAZ-MOR-97-001	75		49		0	0	0	-	-	-
DAZ-N-91-003	28	28	16	16	0	0	0	0	0	0
DAZ-N-94-001	57		7		0	0	0	-	-	-
DAZ-N-95-002	248		315		1(0.32%)	0	2(0.63%)	-	-	-
DAZ-N-95-003	84	84	316	76	0	0	2(0.63%)	0	0	0
DAZ-N/S/DK-95-001	91	91	638	156	0	4(0.63%)	2(0.31%)	0	1(0.64%)	1(0.64%)
DAZ-NL-86-001	31		14		0	0	0	-	-	-
DAZ-NY-83-008	42		8		0	0	0	-	-	-
DAZ-NY-84-001	14		30		0	0	0	-	-	-
DAZ-NY-85-003	56		19		0	0	0	-	-	-
DAZ-NY-85-008	61		12		0	0	0	-	-	-
DAZ-NY-87-006	86		6		0	0	0	-	-	-
DAZ-NY-87-009	14		6		0	0	0	-	-	-
DAZ-NY-87-011	1		1		0	0	0	-	-	-
DAZ-NY-87-022	184	175	16	8	1(6.25%)	0	0	0	0	0
DAZ-NY-87-023	1	1	24	24	0	0	0	0	0	0

**Pooled Comparators includes Placebo and Active Comparators
Date of Table Generation: 17APR2001 13:25:33
Source Data: Appendix 18 - Master, PPG NYHQ Released Project Databases, and BPH NDA
Program Name: L:\SAFETY\CSD\REPORTS\DAZ_ALLHAT_28FEB2001\PGM\APPENDIX 2C.SAS

Appendix 2C: Treatment emergent, All Causality Incidence of Selected Cardiovascular Events, By Protocol ID

	••••Median Duration•••••				••••• Doxazosin/Doxazosin GITS •••••			••••••••• Pooled Comarators •••••••••		
Protocol ID	Doxazosin (Days)	Pooled Compar (Days)	Total # of Subjects on Doxazosin	Total # of Subjects on Pooled Comparators**	Number(%) of Subjects with CHF	Number(%) of Subjects with MI	Number(%) of Subjects with Stroke	Number(%) of Subjects with CHF	Number(%) of Subjects with MI	Number(%) of Subjects with Stroke
DAZ-NY-88-006	12		14		0	0	0	-	-	-
DAZ-NY-89-003	69		25		0	0	0	-	-	-
DAZ-NY-90-001	71	70	29	28	0	1(3.45%)	0	0	0	0
DAZ-NY-90-004	1092	1086	41	39	0	4(9.76%)	0	1(2.56%)	1(2.56%)	2(5.13%)
DAZ-NY-90-008	184	181	23	23	0	0	0	0	0	0
DAZ-NY-90-009	293	366	56	72	0	0	1(1.79%)	0	0	1(1.39%)
DAZ-NY-91-008	87	86	16	16	0	0	0	0	0	0
DAZ-NY-92-001	162	163	8	9	0	0	0	0	0	0
DAZ-NY-92-002	169	168	232	115	0	1(0.43%)	0	0	3(2.61%)	0
DAZ-NY-92-005	84	84	77	73	0	0	0	0	0	0
DAZ-NY-92-008	99	101	102	99	1(0.98%)	0	0	0	1(1.01%)	1(1.01%)
DAZ-NY-92-009	364	363	564	826	4(0.71%)	4(0.71%)	5(0.89%)	3(0.36%)	8(0.97%)	5(0.61%)
DAZ-NY-95-001	95	7	675	1	2(0.30%)	1(0.15%)	0	-	-	-
DAZ-NY-95-002	39	42	8	8	0	0	0	0	0	0
DAZ-P-86-001	12		88		0	0	0	-	-	-
DAZ-PAK-97-002	70		40		0	0	0	-	-	-
DAZ-PAK-97-002A	70		43		0	0	1(2.33%)	-	-	-
DAZ-PE-96-001	100		39		0	0	0	-	-	-
DAZ-PHI-89-001	12		59		0	0	0	-	-	-
DAZ-PHI-90-002	3		137		0	0	0	-	-	-
DAZ-PL-90-001	3		49		0	0	0	-	-	-
DAZ-RU-92-001	71		79		0	0	0	-	-	-
DAZ-S-87-002	180	180	42	42	0	0	0	0	0	0
DAZ-S-90-002	183	182	51	46	0	0	0	0	0	0
DAZ-SA-90-001	86		325		0	0	0	-	-	-
DAZ-SA-92-001	217	308	73	75	0	0	0	0	0	0
DAZ-SA-92-002	112	112	32	30	0	0	0	0	0	0
DAZ-SF-87-001	26		88		0	0	0	-	-	-
DAZ-TR-94-001	98		352		0	0	0	-	-	-
DAZ-TR-95-001	84		181		0	0	0	-	-	-
DAZ-TW-88-001	56		27		0	0	0	-	-	-
DAZ-TW-88-002	24		19		0	0	0	-	-	-
DAZ-TW-88-003	14		30		0	0	0	-	-	-
DAZ-TW-88-004	14		20		0	0	0	-	-	-
DAZ-TW-88-005	15		20		0	0	0	-	-	-
DAZ-TW-92-001	98		21		0	0	0	-	-	-
DAZ-TW-96-001	84	84	15	15	0	0	0	0	0	0
DAZ-TW-96-002	84	84	21	23	0	0	0	0	0	0

**Pooled Comparators includes Placebo and Active Comparators
Date of Table Generation: 17APR2001 13:25:33
Source Data: Appendix 18 - Master, PPG NYHQ Released Project Databases, and BPH NDA
Program Name: L:\SAFETY\CSD\REPORTS\DAZ_ALLHAT_28FEB2001\PGM\APPENDIX 2C.SAS

Pfizer's Response to ALLHAT, 20 April 2001

Appendix 2C: Treatment emergent, All Causality Incidence of Selected Cardiovascular Events, By Protocol ID

Protocol ID	Median Duration Doxazosin (Days)	Median Duration Pooled Compar (Days)	Total # of Subjects on Doxazosin	Total # of Subjects on Pooled Comparators**	Doxazosin/Doxazosin GITS Number(%) of Subjects with CHF	Doxazosin/Doxazosin GITS Number(%) of Subjects with MI	Doxazosin/Doxazosin GITS Number(%) of Subjects with Stroke	Pooled Comarators Number(%) of Subjects with CHF	Pooled Comarators Number(%) of Subjects with MI	Pooled Comarators Number(%) of Subjects with Stroke
DAZ-UK-85-003	91	91	18	18	0	0	0	0	0	0
DAZ-UK-85-015	4		19		0	0	0	-	-	-
DAZ-UK-85-016	90		25		0	0	0	-	-	-
DAZ-UK-86-001	84		18		0	0	0	-	-	-
DAZ-UK-86-002	35	59	14	15	0	0	0	0	0	0
DAZ-UK-86-003	5		31		0	0	0	-	-	-
DAZ-UK-87-006	42	43	25	28	0	0	0	0	0	0
DAZ-UK-87-009	56	56	9	9	0	0	0	0	0	0
DAZ-UK-87-010	56	56	9	9	0	0	0	0	0	0
DAZ-UK-88-002	71		4837		1(0.02%)	3(0.06%)	9(0.19%)	-	-	-
DAZ-UK-88-004	154		5		0	0	0	-	-	-
DAZ-UK-89-002	113		156		0	0	0	-	-	-
DAZ-UK-89-002C	111	96	10	10	0	0	0	0	0	0
DAZ-UK-89-003	88	86	11	11	0	1(9.09%)	0	0	0	0
DAZ-UK-89-004	48	39	11	13	0	0	0	0	0	0
DAZ-UK-90-001	86	87	24	23	0	0	0	0	0	0
DAZ-UK-90-002	84	112	5	4	0	0	0	0	0	0
DAZ-UK-90-003	42	43	21	22	0	0	1(4.76%)	0	0	0
DAZ-UK-90-004	356		60		0	0	0	-	-	-
DAZ-UK-91-002	46		13		0	0	0	-	-	-
DAZ-UK-91-003	7		11		0	0	0	-	-	-
DAZ-UK-91-004	76		4		0	0	0	-	-	-
DAZ-UK-93-001	73	78	28	82	0	0	0	0	0	2(2.44%)
DAZ-URU-97-001	58		4		0	0	0	-	-	-
DAZ-VEN-96-001	105		104		0	0	0	-	-	-
DAZ-WAN-87-001	8		28		1(3.57%)	0	1(3.57%)	-	-	-
I010	203	203	52	48	0	0	0	0	0	0
I015	30	29	50	17	0	0	0	0	0	1(5.88%)
I016	84	84	65	67	0	1(1.54%)	0	0	0	0
I017	133	133	38	19	0	0	0	0	0	0
L-0037	371	372	64	62	1(1.56%)	0	0	0	0	0
L-0298	85	94	22	53	0	0	1(4.55%)	0	0	0
L-0348	141		84		0	1(1.19%)	1(1.19%)	-	-	-
R-0075	98	97	74	70	0	0	0	0	0	0
R-0105	91	90	71	67	0	0	0	0	0	0
R-0111	91	78	112	107	0	0	0	0	0	0
R-0203	108	70	38	32	0	0	0	0	0	0
R-0217	112	126	34	31	0	0	1(2.94%)	0	0	0

**Pooled Comparators includes Placebo and Active Comparators

Date of Table Generation: 17APR2001 13:25:33

Source Data: Appendix 18 - Master, PPG NYHQ Released Project Databases, and BPH NDA

Program Name: L:\SAFETY\CSD\REPORTS\DAZ_ALLHAT_28FEB2001\PGM\APPENDIX 2C.SAS

Appendix 2C: Treatment emergent, All Causality Incidence of Selected Cardiovascular Events, By Protocol ID

	••••Median Duration•••••				••••• Doxazosin/Doxazosin GITS ••••••			••••••••• Pooled Comarators •••••••••		
Protocol ID	Doxazosin (Days)	Pooled Compar (Days)	Total # of Subjects on Doxazosin	Total # of Subjects on Pooled Comparators**	Number(%) of Subjects with CHF	Number(%) of Subjects with MI	Number(%) of Subjects with Stroke	Number(%) of Subjects with CHF	Number(%) of Subjects with MI	Number(%) of Subjects with Stroke
R-0227	63	180	35	42	0	0	0	0	0	0
R-0264	125		12		0	0	0	-	-	-
R-0387	85	87	127	197	0	0	0	0	1(0.51%)	0
R-0388	91		500		4(0.80%)	2(0.40%)	1(0.20%)	-	-	-
R-0407	132	115	48	134	0	0	0	0	1(0.75%)	0

**Pooled Comparators includes Placebo and Active Comparators
Date of Table Generation: 17APR2001 13:25:33
Source Data: Appendix 18 - Master, PPG NYHQ Released Project Databases, and BPH NDA
Program Name: L:\SAFETY\CSD\REPORTS\DAZ_ALLHAT_28FEB2001\PGM\APPENDIX 2C.SAS